Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLand & ImprovementsLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pediatrix Medical (MD) Accumulated Expenses (2022 - 2025)

Pediatrix Medical (MD) has disclosed Accumulated Expenses for 10 consecutive years, with $248.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Accumulated Expenses rose 15.18% to $248.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $248.1 million, a 15.18% increase, with the full-year FY2025 number at $248.1 million, up 15.18% from a year prior.
  • Accumulated Expenses was $248.1 million for Q4 2025 at Pediatrix Medical, up from $2.8 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $248.1 million in Q4 2025 to a low of $2.8 million in Q3 2025.
  • A 4-year average of $127.4 million and a median of $133.6 million in 2025 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: crashed 95.82% in 2023, then skyrocketed 2506.6% in 2024.
  • Pediatrix Medical's Accumulated Expenses stood at $197.8 million in 2022, then plummeted by 95.82% to $8.3 million in 2023, then surged by 2506.6% to $215.4 million in 2024, then grew by 15.18% to $248.1 million in 2025.
  • Per Business Quant, the three most recent readings for MD's Accumulated Expenses are $248.1 million (Q4 2025), $2.8 million (Q3 2025), and $133.6 million (Q2 2025).